TY  - JOUR
A1  - Adelfinger, Marion
A1  - Gentschev, Ivaylo
A1  - de Guibert, Julio Grimm
A1  - Weibel, Stephanie
A1  - Langbein-Laugwitz, Johanna
A1  - Härtl, Barbara
A1  - Escobar, Hugo Murua
A1  - Nolte, Ingo
A1  - Chen, Nanhai G.
A1  - Aguilar, Richard J.
A1  - Yu, Yong A.
A1  - Zhang, Qian
A1  - Frentzen, Alexa
A1  - Szalay, Aladar A.
T1  - Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy
JF  - PLoS ONE
N2  - Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell culture data demonstrate that GLV-5b451 virus efficiently infected, replicated in and destroyed DT09/06 cancer cells. In the selected xenografts of FMC, a single systemic administration of GLV-5b451 led to significant inhibition of tumor growth in comparison to untreated tumor-bearing mice. Furthermore, tumor-specific virus infection led to overproduction of functional scAb GLAF-2, which caused drastic reduction of intratumoral VEGF levels and inhibition of angiogenesis.
In summary, here we have shown, for the first time, that the vaccinia virus strains and especially GLV-5b451 have great potential for effective treatment of FMC in animal model.
KW  - antibodies
KW  - cancer treatment
KW  - carcinomas
KW  - vaccinia virus
KW  - oncolytic viruses
KW  - viral replication
KW  - cell cultures
KW  - enzyme-linked immunoassays
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-119387
VL  - 9
IS  - 8
ER  - 
TY  - JOUR
A1  - Arndt, Andreas
A1  - Hoffacker, Peter
A1  - Zellmer, Konstantin
A1  - Goecer, Oktay
A1  - Recks, Mascha S.
A1  - Kuerten, Stefanie
T1  - Conventional Housing Conditions Attenuate the Development of Experimental Autoimmune Encephalomyelitis
JF  - PLoS ONE
N2  - BACKGROUND:
The etiology of multiple sclerosis (MS) has remained unclear, but a causative contribution of factors outside the central nervous system (CNS) is conceivable. It was recently suggested that gut bacteria trigger the activation of CNS-reactive T cells and the development of demyelinative disease.
METHODS:
C57BL/6 (B6) mice were kept either under specific pathogen free or conventional housing conditions, immunized with the myelin basic protein (MBP)-proteolipid protein (PLP) fusion protein MP4 and the development of EAE was clinically monitored. The germinal center size of the Peyer's patches was determined by immunohistochemistry in addition to the level of total IgG secretion which was assessed by ELISPOT. ELISPOT assays were also used to measure MP4-specific T cell and B cell responses in the Peyer's patches and the spleen. Ear swelling assays were performed to determine the extent of delayed-type hypersensitivity reactions in specific pathogen free and conventionally housed mice.
RESULTS:
In B6 mice that were actively immunized with MP4 and kept under conventional housing conditions clinical disease was significantly attenuated compared to specific pathogen free mice. Conventionally housed mice displayed increased levels of IgG secretion in the Peyer's patches, while the germinal center formation in the gut and the MP4-specific TH17 response in the spleen were diminished after immunization. Accordingly, these mice displayed an attenuated delayed type hypersensitivity (DTH) reaction in ear swelling assays.
CONCLUSIONS:
The data corroborate the notion that housing conditions play a substantial role in the induction of murine EAE and suggest that the presence of gut bacteria might be associated with a decreased immune response to antigens of lower affinity. This concept could be of importance for MS and calls for caution when considering the therapeutic approach to treat patients with antibiotics."
KW  - B cells
KW  - secretion
KW  - multiple sclerosis
KW  - enzyme-linked immunoassays
KW  - Peyer's patches
KW  - gut bacteria
KW  - T cells
KW  - immune response
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-119603
VL  - 9
IS  - 6
ER  -